'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat

Sandoz CEO Richard Saynor said in a statement that steep U.S. tariffs on imported generic drugs could force manufacturers to raise prices or reduce supply. Saynor did not specify which tariffs he was referring to or provide details on potential price increases or supply reductions. Sandoz manufactures generic and biosimilar drugs, with significant sales in the United States market.

Next story